Palatin Technologies

Palatin Technologies is a biopharmaceutical company based in Cranbury, New Jersey. The company has 51 employees and generates $50 million in annual revenue. Palatin (NYSE American: PTN) is a biopharmaceutical company developing medications that target the melanocortin peptide receptor system. This system plays a role in regulating important bodily functions like appetite, energy levels, sexual desire, and the reduction of inflammation. Palatin is focused on developing therapeutics that leverage the melanocortin system to treat a range of conditions, including eye diseases, gastrointestinal issues, and kidney disease. Their most advanced product, PL9643, is a topical treatment for dry eye disease and is slated to begin Phase 3 clinical trials in the second half of 2021. The company's portfolio also includes therapeutics for other ophthalmic conditions like uveitis, retinopathies, and corneal diseases. Palatin is also exploring the potential of melanocortin-based therapies for ulcerative colitis and kidney disease. Their flagship product, Vyleesi®, is the first and only on-demand, FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. To learn more about Palatin Technologies and its product pipeline, visit www.palatin.com. For information on Vyleesi®, including Important Safety Information, please visit www.vyleesi.com/.

Palatin Technologies is a biopharmaceutical company that focuses on developing novel therapeutics. Their primary area of focus is inflammatory and autoimmune diseases, with a particular emphasis on ocular conditions. The company is located in Cranbury, NJ, at 4-B Cedar Brook Drive, Cedar Brook Corporate Center, 08512. Palatin Technologies operates within the healthcare, pharmaceuticals, and biotechnology industries. Palatin Technologies has developed Vyleesi® for women experiencing generalized hypoactive sexual desire disorder (HSDD). The company leverages its expertise in the melanocortin system. Palatin Technologies has over 40 years of experience in drug discovery and development. The company's leadership includes Carl Spana, PhD, who serves as Chief Executive Officer, President, and Director. Stephen T. Wills, CPA, MST, is the Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary. Stephen Slusher is the Chief Legal Officer, and Michael Raizman, MD, is the Chief Medical Officer. John Dodd, PhD, holds the position of Senior Vice President, Preclinical Development, while James Hattersley is the Senior Vice President, Business Development. Robert Jordan serves as Senior Vice President, Program Operations. Paul Kayne, PhD, is the Vice President, Biological Sciences, and J. Don Wang, PhD, is the Vice President, Product Development. The Chairman of the Board of Directors is John K.A. Prendergast, PhD, and Anthony M. Manning, PhD, is a Director. Palatin Technologies' competitive advantages include its extensive experience in drug discovery and development, its expertise in the melanocortin system, and the development of Vyleesi® for HSDD. The company's focus is on inflammatory and autoimmune diseases. Palatin Technologies fosters a science-driven culture, emphasizing innovation and a data-driven approach. They also promote a collaborative working environment. The company can be contacted by phone at 609-495-2200 or via email at [email protected], [email protected], [email protected], and [email protected].